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Abstract: 
 
Associations between blood type and disease have been studied since the early 1900s when 
researchers determined that antibodies and antigens are inherited. In the 1950s, the chemical 
identification of the carbohydrate structure of surface antigens led to the understanding of 
biosynthetic pathways. The blood type is defined by oligosaccharide structures, which are 
specific to the antigens, thus, blood group antigens are secondary gene products, while the 
primary gene products are various glycosyltransferase enzymes that attach the sugar molecules to 
the oligosaccharide chain. Blood group antigens are found on red blood cells, platelets, 
leukocytes, plasma proteins, certain tissues, and various cell surface enzymes, and also exist in 
soluble form in body secretions such as breast milk, seminal fluid, saliva, sweat, gastric 
secretions, urine, and amniotic fluid. Recent advances in technology, biochemistry, and genetics 
have clarified the functional classifications of human blood group antigens, the structure of the 
A, B, H, and Lewis determinants and the enzymes that produce them, and the association of 
blood group antigens with disease risks. Further research to identify differences in the 
biochemical composition of blood group antigens, and the relationship to risks for disease, can 
be important for the identification of targets for the development of nutritional intervention 
strategies, or the identification of druggable targets. 
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INTRODUCTION 
 
Serological research has focused on identifying and understanding the structure, function, and 
interactions of serum antibodies and blood groups. Landsteiner's discovery of blood groups in 
the early 1900s was based on the observation that some individuals' red cells agglutinated when 
mixed with plasma from other individuals.1 His classification of the ABO blood groups and 
subsequent research by others confirmed that antibodies and antigens were inherited 
characteristics.2 In the mid‐1940s, the antiglobulin test was developed, which allowed the 
detection of nonagglutinating antibodies,1 and biochemical genetic investigations were 
undertaken, which established that the specificity of antigens was determined by their 
oligosaccharide structures.2 Thus by definition, blood group antigens are secondary gene 
products; the primary gene products are the various glycosyltransferase enzymes that attach the 
sugar molecules to the oligosaccharide chain. These carbohydrate moieties are recognized as 
foreign by the immune systems of other individuals, which produce antibodies to them.3 
 
Despite the relatively primitive research technology available in the mid‐1900s, intense, 
painstaking, and rigorous scientific research efforts enabled precise chemical identification of the 
carbohydrate structure of a human red blood cell (RBC) surface antigen by 1957, and in 1959 the 
biosynthetic pathways of the antigens known at that time were proposed.2 Since then, 
exponential advances in technology and the sequencing of the genome have resulted in the 
identification of hundreds of blood group antigens, classified into more than 30 blood group 
systems, and the genes which they express have been cloned and sequenced.1 Although the 
molecular genetic sequences are known for these genes and their enzymes have been identified, 
there is still much research to be done in order to fully understand the structure, function, and 
interactions of the antigens they synthesize. 
 
Similarly, human leukocyte antigens (HLAs), which are found on every nucleated cell in the 
human body, have been grouped into major histocompatibility complex (MHC) classes; the 
MHC Class I and Class II HLAs function as antigen‐presenting molecules to activate the 
immune system, while MHC Class III molecules include complement components, heat shock 
proteins, and several lymphotoxins and other factors important in inflammation.4 Nucleated cells 
generate MHC molecules as needed for their immunogenic functions,4 and the HLA antigens and 
other surface markers found on nucleated cells play a vital role in fighting disease. 
 
One of the notable differences between HLA antigens and human blood group antigens is that 
only one phenotype is associated with HLA antigens, while three phenotypes are associated with 
blood group antigens. But the most important difference may be that mature RBCs are 
nonnucleated; all of the blood group antigens are generated prior to maturation, when RBCs lose 
the ability to generate new antigens.1 For this reason, RBCs do not function as antigen‐presenting 
cells. Thus, the association of blood group antigens with disease risk is far more nuanced than 
the association of HLA antigens with diseases. Disease risk is clearly multifactorial and 
causation is not implied by association, but blood group antigens may be one of the predisposing 
factors that contribute to or prevent disease processes. 
 
Table 1 presents these antigens grouped by function, but it should be noted that some antigens 
have more than one function and can therefore be grouped differently with equal justification. As 
researchers continue to identify new blood group antigens and functions, the blood group 
systems and classifications will continue to evolve. Indeed, in the process of compiling 
Table 1 from similar presentations by various authors, the dynamic nature of these classifications 
was readily apparent; not only were new blood groups added over time, but some were renamed, 
and other were reclassified. It is beyond the scope of this review to discuss every human blood 
group antigen, but for those readers who are interested, such discussions can be found in the 
publications referenced in Table 1. 
 
Table 1. Functional Classifications of Human Blood Group Antigens1, 5-9 
Type of Molecule 
System Gene 
Symbol HGNC Symbol1 CD No. Known or Proposed Function No. Name 
Transferase 001 ABO ABO ABO 
 
Prevent infection, cell recognition 
018 H H FUT1 CD173 Prevent infection, cell recognition 
007 Lewis LE FUT3 
 
Prevent infection, cell recognition 
027 I I GCNT2 
 
Prevent infection, cell recognition 
003 P1PK P A4GALT 
 
Prevent infection, cell recognition 
028 Globoside GLOB B3GALT3 
 
Prevent infection, cell recognition, 
Parvovirus B19 receptor 
031 Forssman FORS GBGT1 
 
Prevent infection, cell recognition 
Enzyme 006 Kell KEL KEL CD238 Cell signaling, cleaves Big 
endothelin, Zn‐metalloproteinase 
011 Yt YT ACHE 
 
Esterase 
014 Dombrock DO ART4 CD297 Erythropoiesis, regulate protein 
function, ADP‐ribosyltransferase 
Complement 
regulation 
017 Chido/Rodgers CH/RG C4A, C4B 
 
Compliment component 
021 Cromer CROM CD55 CD55 Compliment regulation; E. 
coli receptor 
022 Knops KN CR1 CD35 Compliment regulation; P. 
falciparum receptor 
Structural 002 MNS MNS GYPA , GYPB , GYPE CD235 
A & B 
Chaperonin 
020 Gerbich GE GYPC CD236 Cytoskeleton attachment to 
membrane; P. falciparum receptor 
Transport/Channel 004 Rh RH RHD , RHCE CD240 
D & 
CE 
Ammonium transport 
030 RHAG RHAG RHAG CD241 RBC membrane integrity, ammonium 
transport 
010 Diego DI SLC4A1 CD233 Band 3, Anion exchange 
015 Colton CO AQP1 
 
Water channel 
029 Gill GIL AQP3 
 
Water channel, urea transport 
009 Kidd JK SLC14A1 
 
Urea transport 
019 Kx XK XK 
 
Transport? 
032 Junior JR ABCG2 
 
ATP‐binding cassette transport 
033 Lan LAN ABCB6 
 
ATP‐binding cassette transport 
Adhesion 023 Indian IN CD44 CD44 Erythropoiesis, binds hyaluronate, 
collagen, fibronectin 
005 Lutheran LU BCAM CD239 Erythropoiesis, binds laminin 
016 Landsteiner‐
Weiner 
LW ICAM4 CD242 Cell‐cell interaction, RBC turnover, 
binds β1‐, β2‐, β3‐, β5‐laminins 
026 John Milton 
Hagen 
JMH SEMA7A CD108 Erythropoiesis, binds RGD 
peptides; P. falciparum receptor 
012 Xg XG XG , CD99 CD991 Apoptosis 
024 Ok OK BSG CD147 Erythropoiesis, binds LFA integrins 
Receptor 008 Duffy FY DARC CD234 Chemokine clearance; P. 
vivax receptor 
012 Scianna SC ERMAP 
 
Signal transduction; IgSF 
025 Raph RAPH CD151 CD151 Signal transduction, binds integrins 
HGNC, Human Genome Organization Gene Nomenclature Committee; IgSF, immunoglobulin superfamily. 
1 Xg glycoprotein excluded. 
 
BLOOD GROUP ANTIGENS 
 
Most antigens are the end product of a single gene, so changes at the genetic level such as 
insertions, deletions, inversions, alternative splicing, or single nucleotide polymorphisms (SNPs) 
lead to antigenic differences, but can also give rise to new antigens or even complete loss of 
expression.3 Human blood group antigens can also be used as receptors by pathogens or 
mimicked by bacteria;6 even small variations in structure are recognized by the immune system, 
which produces antibodies in self‐defense.3 Blood group antigens are found on RBCs, platelets, 
leukocytes, plasma proteins, certain tissues, and various cell surface enzymes,10 and also exist in 
soluble form in body secretions such as breast milk, seminal fluid, saliva, sweat, gastric 
secretions, urine, and amniotic fluid.1 The ABO blood group antigens are perhaps the most 
important and widely studied, and were the first to be identified.11 
 
 
Figure 1. Antigen structures generated from Type 1 precursor chains, which are primarily found 
in body secretions. 
 
The initial interactions of the ABO , Hh , Sese , and Lele genes were derived in 1959 from the 
double‐helix structure of DNA and the inheritance patterns of the A, B, H, Lea, and Leb antigens, 
and although these pathways have been revised as new information was obtained, the basic 
premise was correct.2 The primary structure of these antigens is either a glycolipid or a 
glycoprotein, with an oligosaccharide ‘precursor’ sequence and one or more specific sugar 
molecules attached to it in specific locations.10 The five blood group antigens, A, B, H, Lea, and 
Leb, are produced from the enzymes expressed by these four genes and are the basis of the ABO 
‘blood type’ phenotypes.2 It is important to understand the relationship between 
the ABO , Hh , Sese (secretor), and Lele (Lewis) genes, because they each play different roles in 
the final ABO antigen structure of an individual's body tissues and secretions. 
 
There are two precursor oligosaccharide sequences for ABO(H) antigens, which only differ in 
their terminal residues; Type 1 chains end with a Gal β1‐3 GlcNAc β1‐R sequence (Figure 1), 
and Type 2 chains end with a Gal β1‐4 GlcNAc β1‐R sequence (Figure 2).1, 10 Only the precursor 
Type 1 chain is required for Lea antigen formation. Leb is a hybrid of the H antigen and Lea. 
Similarly, only the precursor Type 2 chain is required for Lex antigen formation but Ley is a 
hybrid of the H antigen and Lex. There are two α1,2‐fucosyltransferases with different acceptor 
specificity and tissue‐specific expression: one is a product of the H gene located in hematopoietic 
tissues, and the other is a product of the Se gene located in secretory tissues. 
 
 
Figure 2. Antigen structures generated from Type 2 precursor chains, which are primarily found 
on body tissues and RBCs. 
 
Only Type 2 chains are found on RBCs and other body tissues (primarily epithelial and 
endothelial cells11) and are not affected by secretor status; while both Type 1 and Type 2, but 
primarily Type 1, chains are found in secretions of those who are secretors (Se/Se or Se/se ), 
neither are found in those who are nonsecretors (se/se ).10 The fucosyltransferase expressed by 
the Sese gene (subsequently identified as the FUT2 gene) is found in secretory glands and 
attaches fucose in α1‐2 linkage to the terminal galactose residue of both Type 1 and Type 2 
chains.10 The Sese gene does not affect the production of the ABO antigens found in the plasma 
or the secretion status of other antigens.1 
 
The fucosyltransferase expressed by the H gene (subsequently identified as the FUT1 gene) is 
found in hematopoietic tissues and attaches fucose in α1‐2 linkage to the terminal galactose 
residue of Type 2 chains.10 This H antigen completes the acceptor substrate and is required for 
attachment of the final monosaccharide that distinguishes the A and B antigens.1 In non‐O blood 
group individuals, the N‐acetylgalactosaminyltransferase expressed by individuals with 
an A allele attaches N‐acetylgalactosamine in α1‐3 linkage to the terminal galactose residue of 
Type 1 and Type 2 chains, while the galactosyltransferase expressed by those with a B allele 
adds galactose in α1‐3 linkage to those residues.1, 10 
 
Even though the H antigen is expressed in individuals who are homozygous for the O allele, they 
do not form A or B antigens because they lack both of the glycosyltransferase enzymes that 
attach the final monosaccharide to the oligosaccharide chain.1, 10 In contrast, individuals who are 
homozygous h/h , known as the Bombay phenotype, do not generate the necessary substrate to 
form the A and B antigens, even when they have the A or B allele and the necessary 
glycosyltransferase enzymes.1, 10 
 
The antigens of the Lewis blood group system are unique in several ways. The Le gene 
(subsequently identified as the FUT3 gene) expresses a fucosyltransferase that adds fucose in α1‐
4 linkage to the subterminal GlcNAc of the Type 1 chain only; galactose is already in α1‐4 
linkage to the subterminal GlcNAc of the Type 2 chain.10 The le allele is silent, while 
the Le allele produces a single antigen that is found as Lea in nonsecretors (a glycosphingolipid 
with the oligosaccharide chain attached via d ‐glucose) and as Leb in secretors (a glycoprotein 
with the oligosaccharide chain attached via N‐acetyl‐d ‐galactosamine).10 Thus, the Le(a+b−) or 
Lea individual is a nonsecretor (Le and se/se ), the Le(a−b+) or Leb individual is a secretor 
(Le and either Se/Se or Se/se ), while the Le(a−b–) individual (le/le ) can be either a secretor or 
nonsecretor.1 In a similar manner, the addition of fucose in α1‐3 linkage to the subterminal 
GlcNAc of the Type 2 chain generates the Lex and Ley antigens. In the plasma, the Lewis blood 
group antigens are attached to circulating RBCs, platelets, and lymphocytes by direct insertion of 
their lipid anchor into the plasma membrane of these cells; in the body secretions, the Lewis 
antigens are similarly attached by the amino acid component of the glycoprotein.10 
 
The Rh blood group system is the most complex, and perhaps the second most studied blood 
group system. There are 49 known antigens in the Rh system,12 with the D, C/c, and E/e antigens 
as the major types13 expressed by the RHD and RHCE genes in the RH locus. The D antigen is a 
polypeptide produced by the RHD gene, while the RHCE gene produces a polypeptide with the 
C/c and E/e antigens; the remaining antigens are produced by partial deletion, recombination, 
mutation, or polymorphisms of one or both genes.13 RhD‐positive people have the RHD gene, 
while RhD‐negative people are missing the RHD gene; there are significant differences in the 
racial frequency of the RhD‐negative genotype, which can be traced back to Paleolithic and 
Neolithic ancestry.12 
 
The ABO, Lewis, and Rh blood group systems demonstrate how antigens can be grouped based 
on structural homology, secondary structure, and biological function of certain molecules; once 
structure is defined, antigens can be classified into functional categories of structural proteins; 
enzymes; transporters and channels; adhesion molecules; and receptors for exogenous ligands, 
viruses, bacteria, and parasites.8, 9 Because structure often dictates function, when function is not 
known, antigens can be classified based on similarity of structure.9 As our knowledge of 
molecular genetics increases, we are better able to understand the role of antigens and study the 
relation between structure and function.11 
 
BLOOD GROUPS AND DISEASE 
 
Because much of the research on blood antigens has focused on understanding blood 
transfusions, the antigens are commonly referred to as blood group antigens.14 Blood group 
antigens are primarily tissue antigens, and are widely distributed throughout the body. The 
antigens evolved earlier in ectodermal and endodermal tissue than in RBCs and hematopoietic 
cells, and for this reason are also referred to as histo‐blood group antigens.14 Antibodies to these 
tissue antigens cause rejection of transplanted tissues and organs11 and can cause spontaneous 
abortions.14 
 
Both the ABO and Rh blood groups systems have been associated with a number of diseases, but 
this is more likely related to the presence or absence of these tissue antigens throughout the body 
and not directly or primarily related to their presence on RBCs.14 Although early research relied 
on using statistical methods to associate the blood groups with diseases such as infection, 
malignancy, and coagulation, these associations have more recently been given scientific 
validation through extensive research in infectious disease, tumor immunology, and membrane 
chemistry.14 
 
Some of the known associations between blood group antigens and disease are presented here 
and summarized in Table 2. Research is complicated for several reasons: the ABO blood group 
system is highly polymorphic, with more than 20 distinct subgroups; study findings are usually 
related to ABO phenotype, but rarely to the ABO genotype, secretor status, and Lewis 
phenotype; and animal models are unsatisfactory because their antigen glycosylation structure is 
different from humans.15 Molecular biology techniques, transgenic animals, and computer 
modeling are being explored as possible investigative tools for studying the complex 
mechanisms and processes involved in glycosylation, and how glycosylation affects proteins and 
individual cells, as well as entire organisms; the lack of adequately robust analytical tools is 
perhaps the biggest impediment faced by researchers.15 
 
Table 2. The Relationship of Blood Group with Disease Risks 
Disease Risk Factor Blood Group/Antigens 
Sickle cell anemia16 Increased adhesion Adhesion Molecules 
Hemolytic disease of the newborn12, 18 Antibodies to RhD RhD 
Chronic and autoimmune hemolytic anemias13, 18 Rh null Rh, RhAG 
Vascular disorders, venous and arterial thromboembolism, 
coronary heart disease, ischemic stroke, myocardial 
infarction1, 11, 14, 19-23 
Reduced clearance of von 
Willebrand factor and FVIII 
Groups A > AB > B 
Dementia, cognitive impairment23, 24 Coagulation factors Groups AB > B > A 
Plague, cholera, tuberculosis, mumps14 Antigen profile Group O 
Smallpox, Pseudomonas aeruginosa 14 Antigen profile Group A 
Gonorrhea, tuberculosis, S. pneumoniae , E. coli , salmonella14 Antigen profile Group B 
Smallpox, E. coli , salmonella14 Antigen profile Group AB 
N. meningitides , H. influenza , C. albicans , S. pneumoniae , E. 
coli urinary tract infections, S. pyogenes , V. cholera 1, 14, 25 
Antigen profile Nonsecretors 
Disease Risk Factor Blood Group/Antigens 
H. pylori 1, 11, 14, 26, 27 Strain‐dependent Group A; 95% non‐O 
Peptic ulcers, gastroduodenal disease11, 14, 26 Secretor status, H. pylori strain All nonsecretors; Group O 
Norovirus1, 11, 28-30 Strain‐dependent Secretors; groups O, A 
P. falciparum malaria1, 11, 31 Receptor/antigen profile Knops antigens; groups A, 
B 
P. vivax malaria31 Antigen profile Duffy FY antigens 
Cholera28 Severity differs by antigen 
profile 
Lewis antigen; 
nonsecretors; non‐O 
groups 
Bacterial meningitis (N. meningitidis , H. influenza , S. 
pneumoniae )32 
Antigen profile Nonsecretors; A, AB, O 
blood groups 
Cancer (tissue specific)1, 11, 14, 33-38 Increased tumor antigens and 
ligands 
A, B, H antigens lost; ‘A‐
like’ antigens gained 
Leukemia and lymphoma14, 39 RBC membrane changes A, B, H antigens lost 
Non‐Hodgkin's central nervous system lymphoma (primary 
and secondary)40-42 
 
Group O, B 
Hodgkin's lymphoma42 
 
Group B 
Acute lymphoblastic leukemia42, 43 
 
Group O 
Acute myeloid leukemia1, 42, 43 
 
Group A 
Stomach cancer21, 27, 44 H. pylori strain Group A 
Pancreatic cancer1, 11, 21, 45 H. pylori strain Group B > AB > A 
Von Hippel‐Lindau and neuroendocrine46 Multiple tumors Group O 
Multiple endocrine neoplasia type 147 Strongly associated Group O 
Colon/Rectum cancer1, 48, 49 Type 1 and 2 chains; Lewis 
antigens 
Secretors; ‘A‐like’ 
antigens expressed 
Hypertension15, 50-53 Three phenotypes differ Group B > A > AB 
Hyperlipidemia15, 50, 54-56 Low fat diet Ineffective; 
Intestinal ALP and apoB‐48 
vary by secretor status 
LDL: heterozygous MN; 
Group A, B; 
ALP/apoB‐48: Group O 
and B secretors 
Type 2 diabetes19, 15, 50, 57-60 Rh group modifies Group AB > B > A 
Type 1 diabetes30, 59, 60 FUT2 gene locus Nonsecretors 
The risk factors and blood groups or antigens associated with various diseases, based on the research presented in 
this review. 
 
Role of Cell Adhesion Molecules in Disease 
 
Although the exact mechanisms are not yet known that will explain all of the reported 
associations between blood group antigens and disease, what is known about their structure and 
functions provides some intriguing clues. An unexpected number of the antigenic structures 
found on RBCs act as cell adhesion molecules (CAMs); some contribute to normal RBC 
development and some play a role in human disease.16, 17 These antigens can serve as receptors 
and ligands for microbes, and may play a role in movement of normal and malignant cells 
throughout the body.14 CAM moieties include carbohydrates, glycosylphosphatidylinositol‐
anchored proteins, and transmembrane proteins,16 and are grouped into five families: cadherins, 
selectins, integrins, the immunoglobulin superfamily (IgSF), and cell surface proteoglycans; 
blood group antigens are associated with all but cadherins.14 Selectins are expressed by 
leukocytes, platelets, and endothelial cells, and RBCs are capable of binding to them.16 Selectins 
participate in attaching leukocytes to endothelial cells, and integrins participate in cell‐to‐cell and 
cell‐to matrix communication.14 Selectins, integrins, the IgSF, the cartilage link protein family, 
and sialomucins play a role in hematopoiesis.16, 17 
 
RBCs, especially sickled red cells, contain sialylated glycolipids and glycoproteins, which 
facilitate cell‐cell interactions.16 Sickle RBCs are strongly adherent to thrombospondin, 
fibronectin, and especially to laminin; adhesion to endothelial cells induces pathological changes 
in them, especially cell retraction and upregulation of procoagulants and adhesion 
molecules.16 RBCs are also responsive to epinephrine, with sickle RBCs showing significantly 
more responsiveness and greater adherence postexposure.16 The adhesion receptor CD44, a 
cartilage link protein, is primarily a receptor for hyaluronan, but also binds to fibronectin, 
osteopontin, and endothelial cells; it mediates aggregation of leukocytes and T‐cell activation, 
cooperates with integrin to bind erythroid progenitor cells to bone marrow matrix fibronectin; 
and anchors tumor cells during metastasis.16 
 
Hemolytic Diseases 
 
In the early 1940s, maternal antibodies to the RhD antigen of the fetus were identified as the 
cause of hemolytic disease of the newborn (HDN),12 which can now be prevented by 
administration of Ig anti‐D to the RhD‐negative mother upon delivery; this prevents the 
formation of antibodies to RhD.18 In addition to the RhD‐negative genotype, there is an 
extremely rare Rh‐null genotype, in which the RBCs lack all Rh antigens, resulting in membrane 
polypeptides that are missing or severely deficient, and abnormalities in RBC shape, membrane 
phospholipid organization, and cation transport.13 There are two Rh‐null types: the amorph type 
is associated with a silent allele due to a mutation of the RHCE gene in a RhD‐negative person, 
while the regulator type is due to homozygosity of an autosomal suppressor gene unrelated to 
the RH locus.18 
 
All Rh antigens can potentially play a role in autoimmune hemolytic anemias as well as 
hemolytic reactions due to immune activation following pregnancy or transfusion, but Rh‐null 
individuals experience chronic hemolytic anemias of nonimmune origin. Further investigations 
into the Rh‐null phenotype revealed that Rh antigens are part of a noncovalently bound complex 
of proteins, with a core tetramer of two Rh and two Rh‐associated glycoprotein (RhAG) 
subunits, and CD47, LW, and GPB accessory proteins; this complex is anchored in the lipid 
bilayer by the N‐terminal and C‐terminal domains of the Rh and RhAG proteins.18 This complex 
is linked to the actin‐spectrin based cytoskeleton of the RBC through direct interaction with 
protein 4.2 and ankyrin, and with protein Band 3, the erythroid anion exchanger, through their 
common interaction with ankyrin; when Rh or RhAG proteins are missing, this complex is not 
assembled or transported to the cell membrane, resulting in the characteristic osmotic fragility 
and RBC abnormalities found in chronic hemolytic anemia.18 
 
Circulatory Diseases 
 
Historically, non‐O blood groups have been associated with greater incidence of vascular 
disorders such as cerebral arterial ischemia, venous thromboembolism, peripheral vascular 
disease, angina, and myocardial infarction, and these associations were confirmed in 2008 with a 
systematic review and meta‐analysis, and further validated by subsequent GWAS 
studies.1 Recent reviews of the published literature quantified the risk in non‐O blood group 
individuals for venous thrombosis (OR = 1.79), peripheral vascular disease (OR = 1.45), 
coronary heart disease (OR = 1.25), myocardial infarction (OR = 1.25), and ischemic stroke (OR 
= 1.14), as compared with blood group O individuals.19, 21 von Willebrand factor (vWF) and 
Factor VIII (FVIII) are plasma coagulation glycoproteins, which act by forming a noncovalently 
bound complex; vWF stabilizes FVIII and transports it to the site of vascular injury, and then 
interacts with platelets as part of the clotting process.1 vWF is partially regulated by the cleavage 
action of a metalloprotease, which clears it from the plasma; it is thought that the A and B 
antigens interfere with access to the cleavage site, thereby reducing clearance of vWF.1 
 
FVIII and vWF are approximately 25–30% lower in the plasma of blood group O people 
(specifically, Bombay < O < B < A < AB, with A/O and B/O having less than A/A and B/B 
individuals), and group O individuals are therefore at lower risk for venous and arterial 
thromboembolism, but at greater risk of excessive bleeding than group A 
individuals.1, 11, 14 Higher average levels of FVIII in blood group A individuals increase the risk 
of ischemic heart disease and venous thromboembolism,11 and group A people are more likely to 
thrombose or have myocardial infarctions than group O individuals.14 The risk for myocardial 
infarction in the presence of coronary atherosclerosis is 44% lower for group O individuals than 
for other blood groups.11 Non‐O blood group individuals have an 11% greater relative risk of 
developing coronary heart disease than blood group O individuals,20 and group AB individuals 
have a high risk of stroke compared to group O individuals.18 A recent report found that 60% of 
stroke risk in blood group AB individuals was associated with FVIII levels.22 
 
Cognitive Disorders 
 
In addition to their association with circulatory diseases, higher levels of vWF and FVIII in non‐
O blood group individuals have been associated with increased risk of dementia and cognitive 
impairment, indicating that coagulation factors may play a role in these disorders.23 A large 
prospective case–control study found an increased risk of cognitive impairment (OR = 1.82) in 
blood group AB individuals, which was independent of age, race, gender, or geographic region, 
and that FVIII levels differed significantly by blood group, with O < A < B < AB.22 This study 
also found that hypertension, dyslipidemia, obesity, diabetes, and cardiovascular disease (CVD) 
were more prevalent in those with cognitive impairment, which indicates that a common etiology 
is likely; blood group influences CVD risk and CVD risk factors are known to be associated with 
dementia and cognitive impairment. Interestingly, blood groups B and AB were more frequent in 
blacks (in both cases and controls),22 which may be an overlooked factor in increased rates of 
stroke and CVD in this population. 
 
Bacteria, Viruses, and Parasites 
 
Epithelial cells express ABH and Lewis antigens, which are effectively cell‐surface 
glycoconjugates used by parasites, bacteria, and viruses as receptors for attachment, resulting in 
different susceptibilities depending on the antigen profile of an individual.11 By using the same 
blood group antigens as their host, certain microbial parasites utilize molecular mimicry as a 
defense against the host's immune system.11 The chemical signatures on the membranes of many 
gram‐negative organisms such as Escherichia coli resemble A and B blood group antigens; in 
vitro experiments have shown that anti‐B antibodies kill E. coli , and anti‐A and anti‐B 
antibodies may therefore play a similar role in destroying gram‐negative bacteria in vivo .14 
 
Type O blood group is associated with increased incidence of plague, cholera, mumps, and 
tuberculosis infections; type A blood group is associated with increased incidence of smallpox 
and Pseudomonas aeruginosa infection; type B blood group is associated with increased 
incidence of gonorrhea, tuberculosis, Streptococcus pneumoniae , E. coli , 
and salmonella infections; and type AB blood group is associated with increased incidence of 
smallpox, E. coli , and salmonella infections.14 Nonsecretors have an increased incidence 
of Neisseria meningitides , Haemophilus influenza , Candida albicans ,14 S. pneumoniae , E. 
coli urinary tract infections,1 Streptococcus pyogenes , and Vibrio cholera e.24 
 
Helicobacter pylori 
 
In 1954, it was reported that the incidence of peptic ulcers (gastric and duodenal) was 20% 
higher for group O individuals than group A individuals, with the incidence of duodenal ulcers 
35% higher in group O individuals than in group A, B, and AB individuals, and 50% higher in 
nonsecretors (who make up 20% of the population).14 For group A and B nonsecretors, the 
relative risk was 1:6; for group O secretors, the relative risk was 1:35; and for group O 
nonsecretors, the relative risk was 2:5.14 Secretor status and H. pylori infection are independent 
and significant risk factors for gastroduodenal disease, with a relative risk of 1.9 for nonsecretors 
versus secretors.25 Although gastritis and gastric ulcers are associated with H. pylori infection, 
more recent studies have reported that different strains of H. pylori showed varying preferences 
for each blood group antigen, and in fact, 95% of the strains did not show a preference for blood 
group O antigens.11 Interestingly, although only 5% of the strains prefer the H antigen in the 
general population, in those of American Indian heritage (a group O‐dominant population), 60% 
of the strains show this preference.11 
 
Noroviruses 
 
The Norovirus appears to be another strain‐dependent pathogen, but blood group B individuals 
have less risk of infection (OR, 0.096) and symptomatic disease (OR, 0), and group O 
individuals have a much greater risk of infection (OR, 11.8).11 The Norovirus binds to 
difucosylated Lewis antigens (secretors) and to A and H antigens, and but not to B 
antigens,27 while nonsecretors appear to be resistant to symptomatic infection with most 
strains.1 In three outbreaks in Sweden, 29% of nonsecretors were asymptomatic, while among 
those with symptoms, none were nonsecretors (se/se ); 51% were heterozygous (Se/se ) and 49% 
were homozygous (Se/Se ).1 However, recent research has shown that nonsecretors are not 
immune to infection; the genogroup and genotype of the Norovirus strains have different binding 
capacities due to extensive structural differences in certain domains of the capsid protein, which 
are critical for attachment to host cells and determine whether binding can occur in 
nonsecretors.28 Although nonsecretor status provides resistance to Norovirus infection, it is 
thought to increase susceptibility to Crohn's disease and to autoimmune gastritis, which increases 
the risk of malabsorption and deficiency of vitamin B12, and the risk of pernicious anemia.29 
 
Malaria 
 
There are four species of Plasmodium , but the most virulent is P. falciparum , which accounts 
for 50% of the cases and 80% of the deaths, while P. vivax accounts for another 40% of 
cases.30 The Duffy blood group system, which has six discrete antigens, is involved in P. 
vivax infections; mutations of the FY gene that result in RBCs without the Duffy antigen protect 
against infection by this strain of malaria.30 The Knops blood group system, which has nine 
discrete antigens, appears to play a role in the severity of P. falciparum infection; mutations of 
several of these antigens appear to provide a protective effect in African blacks.30 
 
The severity of P. falciparum malaria is directly correlated with the presence or absence of blood 
group A and B antigens; O blood group individuals tend to be less severely affected by malaria, 
while A and B blood group individuals are at greater risk of malarial anemia (OR, 
1.18).11 Infected RBCs express membrane proteins that bind the A antigen, and possibly to a 
lesser extent the B antigen, of uninfected RBCs, forming large clusters or rosettes; RBCs with 
just the H antigen form smaller and less robust rosettes,1 while RBCs with the A antigen form 
larger and stronger rosettes.30 A and B antigens also act as adhesion molecules during 
sequestration, allowing infected RBCs to adhere to the microvascular endothelial cells, which 
remove them from circulation and protect the parasite from destruction, but also block 
circulation and reduce oxygen supply.1, 11 Rosetting and sequestration correlate with the 
increased severity of malaria and contribute to the high mortality rate among children with 
cerebral malaria; this is a major selection pressure behind the population distribution of those 
with blood group O relative to non‐O in the areas of the world where malaria is still 
prevalent.1, 11 
 
Cholera 
 
The predominant cause of endemic and epidemic cholera is the bacteria Vibrio cholera O1, 
which has been associated with a lower risk of colonization in exposed blood group O 
individuals, but a higher risk of more severe disease if colonized in those individuals.28 A study 
in Bangladesh reported the distribution of O:A:B:AB blood groups in healthy controls as 28%, 
23%, 38%, and 11%, respectively; in patients as 43%, 19%, 34%, and 4%, respectively; and in 
asymptomatic contacts as 47%, 18%, 27%, and 8%, respectively.28 This study found that the 
Lewis antigen was significantly different in symptomatic cholera infections, when compared to 
controls and healthy contacts. 
 
The overall distribution in the study participants was 28% Le(a+b–) or nonsecretors with the 
Lewis antigen, 55% Le(a−b+) or secretors with the Lewis antigen, and 17% Le(a−b–), who do 
not express the Lewis antigen and can be either secretors or nonsecretors.28 Comparing cholera 
patients versus contacts/healthy controls, the distribution was 39% versus 25%/25% Le(a+b–), 
40% versus 60%/58% Le(a−b+), and 21% versus 15%/17% Le(a−b–), indicating that 
nonsecretors were more likely to get symptomatic cholera than contacts (OR, 1.91) and healthy 
controls (OR, 1.90), and that secretors were less likely than contacts (OR, 0.45) and healthy 
controls (OR, 0.48), while no difference was found in the Lewis‐null group.28 
 
When comparing patients to contacts by blood group, within the A and B blood groups the 
secretor phenotype was significantly less common, while nonsecretors and Lewis‐null 
phenotypes were more common; this difference was not seen in the O blood group individuals, 
but since this blood group is itself a risk factor for cholera, the Lewis blood group effect may 
have been masked.28 Additionally, secretors required less intravenous fluid than nonsecretors, 
which is consistent with the severity findings, and Lewis‐null individuals had the longest 
duration of diarrhea and required the most intravenous fluids, suggesting an increased severity of 
infection if it occurs; this may be related to the finding that the Lewis‐null group also had the 
lowest IgA response to lipopolysaccharide antigens at day 7.28 
 
Bacterial Meningitis 
 
Three species of bacteria, N. meningitides , H. influenza , and S. pneumoniae , cause about 75% 
of all bacterial meningitis; the capsules of these bacteria contain polysaccharide antigens, which 
the immune defense of the host must recognize and respond to with the appropriate 
antibodies.32 These bacteria can generate either A or B antigens, depending on the blood group 
environment in which they find themselves, and also contain an enzyme that can alter B antigen 
to A antigen; perhaps not surprisingly, blood group B individuals have the lowest prevalence of 
infection by these bacteria because their anti‐A antibodies respond as natural antibodies to the 
bacterial antigens.32 In contrast, blood group A, AB, and O individuals must rely on specific anti‐
pneumococcal antibodies, which their immune system must generate in response to the invading 
organisms.32 Nonsecretors are significantly more susceptible to these bacteria than secretors; 
nonsecretors make up 20–25% of the general population of western Europe, but in several 
studies, the proportion of nonsecretors in patients with these infections ranged from 47.0% to 
73.3%.32 
 
BOX 1. MOSQUITO‐BORNE DISEASES 
Mosquito‐borne diseases add layers of complexity to the efforts to correlate blood groups with 
disease risk, and highlight the need for interdisciplinary, collaborative research. 
The Aedes mosquito is the common vector for transmission of yellow fever, dengue fever, 
chikungunya, and zika viruses; a common vector increases the risk of host co‐infections, and 
the risk of genetic recombination and reassortment in these viruses.61 Both dengue and 
chikungunya infections can be asymptomatic, mild, severe, or fatal, and similarity of 
symptoms results in misclassification without laboratory diagnosis.62 Studies must also 
consider normal blood group distribution frequencies for affected populations, as well as the 
number of serotypes, topotypes, subtypes, clades, and strains for a given virus, especially if 
some are more virulent than others (as seen with malarial parasites). Even landing preferences 
and feeding patterns of mosquitoes may affect blood group infection rates; Aedes mosquitoes 
were reported to be more attracted to some host blood types than others.63, 64 There are no 
published studies correlating blood groups with zika virus, and only a few for dengue or 
chikungunya fever;65-69 the findings of one68 are consistent with gene association 
studies,70 which found that the AB blood group (which lacks antibodies to both A and B 
antigens) was independently associated with increased susceptibility to severe dengue 
hemorrhagic fever in secondary infections. Understanding how blood group antigens affect 
disease risk, prevalence, and severity will contribute to more effective prevention, improved 
treatments, and faster vaccine development. Time is of the essence, and right now, the 
mosquitoes are winning. 
 
Cancer 
 
Blood group antigens participate in cell signaling, cell recognition, and cell adhesion, and are 
therefore likely to play a role in tumorigenesis, metastasis, and prognosis.47 During cellular 
differentiation, development, and aging, expression of ABH and related antigens varies; this is 
particularly true during pathological phenomena and carcinogenesis.11 The epithelial tissues of 
the mouth, gastrointestinal tract, lung, bladder, breast, uterine cervix, and prostate have ABH 
antigens, but these antigens are often missing from the glycoproteins and glycolipids of 
malignant tissues in these areas.1 For example, it is thought that DNA methylation in the 
promoter region for the blood group A gene may inhibit transcription of the associated enzyme 
and therefore loss of the A antigen, but different mechanisms for reduction of mRNA have been 
found in A tumors, which appear to be specific to each tumor cell line.36 
 
Loss of A and B antigens precedes metastasis, results from down‐regulated transcription of ABO 
with associated loss of A‐ or B‐transferase activity, and increases accumulation of other antigens 
which act as ligands for selectins and facilitate the metastatic process.1 As malignancy 
progresses, normal antigens are lost and so‐called tumor antigens are acquired; the decrease in A, 
B, and H antigens is inversely proportional to the metastatic potential of the tumor.14 Blood 
group antigens are known to have procoagulant and angiogenic properties, act as ligands for 
selectins, increase cellular motility, and increase resistance to apoptosis; these biological roles 
may facilitate tumor progression, and a model has been proposed that may account for the 
described associations between the presence or loss of these markers and the outcome of 
disease.71 
 
Some people who are not blood group A have tumors with true A antigens or with ‘A‐like’ 
antigens that have very similar properties to A antigens; in these people, the tumor antigens 
would be recognized as foreign and would interact with anti‐A antibodies, resulting in attack of 
the tumor.14 This may explain why blood group A people have a higher incidence of cancer than 
group O people; the A or ‘A‐like’ properties of these tumor antigens are not seen as foreign in 
blood group A people.14 When compared to group O people, group A people have a higher 
incidence of cancer in the salivary glands (64%); stomach (22%); ovaries (28%); uterus (15%); 
cervix (13%); and colon/rectum (11%).14 It should be noted that although ABO genotypes are 
significantly correlated with the risk of certain cancers, they do not cause cancer; they only 
indicate susceptibility.11 Conversely, lack of correlation does not confer protection: multiple 
studies have failed to find an association between blood type and breast cancer.33-35, 38 
 
Leukemia and Lymphoma 
 
In patients with acute leukemia, and sometimes in aplastic anemia, A and B antigens commonly 
decrease until they are undetectable; as the patient's condition improves, the antigens increase 
again to their former levels.14 This loss of antigens may not be due to deficiency in transferase 
synthesis or activity, but instead may be due to an inhibitory factor related to antigen‐antibody 
binding, or an abnormal distribution or density of antigen sites in the RBC membrane.39 In 
patients with leukemia, between 17% and 37% had significantly lower expression of A, B, or H 
antigens when compared to healthy controls; of A, B, or AB patients with myeloid malignancies, 
55% had reduced expression of A or B antigens, and 21% of O patients had reduced H antigens, 
when compared with healthy controls of the same ABO genotype.1 
 
Non‐Hodgkin's primary central nervous system lymphoma (PCNSL) begins in and typically 
remains confined to the central nervous system (CNS),41 while secondary central nervous system 
lymphoma (SCNSL) typically does not begin in the CNS but may later involve the CNS in 10–
30% of cases.40 A multicenter study of 36 patients with PCNSL reported that the incidence was 
55.6% in blood group O, 8.3% in blood group A, 27.8% in blood group B, and 8.3% in blood 
group AB,41 while a second study evaluated 202 patients with secondary central nervous system 
lymphoma (SCNSL), and reported that the incidence was 29.7% in blood group O, 5.0% in 
blood group A, 61.9% in blood group B, and 3.5% in blood group AB.40 In both studies, the 
same population of healthy controls was used, in which the blood group proportions were 35.6% 
in blood group O, 37.1% in blood group A, 22.2% in blood group B, and 6.1% in blood group 
AB; the dramatically lower incidence in blood group A in both studies is highly significant in 
light of the fact that blood group A is the most common blood group in Iran.40, 41 
 
There are very few studies of the association between ABO blood groups and children with 
leukemia and lymphoma. A 10‐year retrospective study of pediatric patients with acute myeloid 
leukemia (AML; n = 116), acute lymphoblastic leukemia (ALL; n = 522), Hodgkin's lymphoma 
(n = 63), and non‐Hodgkin's lymphoma (n = 78) reported significant differences in the overall 
distribution of blood groups when compared to the source population for all but the AML 
patients.42 This study reported that the incidence of Hodgkin's lymphoma was 45.6% higher in 
blood group B patients and 56.5% lower in blood group A patients; the incidence of non‐
Hodgkin's lymphoma was 52.9% lower in blood group A patients; the incidence of ALL was 
14.3% higher in blood group O patients; but there was no difference in the distribution of blood 
groups in patients with AML.42 A separate multicenter pediatric study of 682 patients with ALL 
and 224 patients with AML reported the incidence of ALL was 56.5% higher in blood group O 
patients, 35.8% lower in blood group A patients, and 26.9% lower in blood group B patients, 
while the incidence of AML was 28.8% higher in blood group A patients.43 
 
Stomach Cancer 
 
Worldwide, gastric cancer is the fourth most common type of cancer and the second leading 
cause of cancer deaths; studies since the 1950s have consistently shown that blood group A 
individuals have about a 20% greater risk of stomach cancer than blood group O individuals.21 A 
meta‐analysis in 2012 gave group A individuals an odds ratio of 1.11 and group O individuals an 
odds ratio of 0.91 for gastric cancer, and also found that blood group A individuals had 
significantly higher rates of H. pylori infection that non‐A blood group patients (OR = 1.42).44 
This is significant because a recent investigation of ABO blood groups and H. pylori found that 
the risk of advanced precancerous gastric lesions was significantly affected by the presence or 
absence in the bacterial DNA of two SNPs in the cytotoxin‐associated gene A (CagA ), 
distinguished as CagA positive and CagA negative strains.27 
 
In individuals infected with CagA positive H. pylori , the risk was significantly higher in blood 
group A than in blood group O for intestinal metaplasia (OR = 1.36) and dysplasia (OR = 1.78), 
with a combined OR of 1.42, while in those with CagA negative strains or who were not infected 
with H. pylori , blood group A individuals had a significantly lower risk than blood group O 
individuals for intestinal metaplasia and dysplasia (OR = 0.60).27 Thus, ABO blood group is a 
risk factor in the development of precancerous lesions in individuals with CagA positive H. 
pylori infection; ABO antigens on the gastric epithelium are binding sites for the H. pylori 
bacterium, which then injects CagA virulence protein into the cellular cytoplasm.27 Both factors 
play a role in the severity of gastric precancerous lesions and progression to gastric cancer. 
 
Pancreatic Cancer 
 
Pancreatic cancer is the seventh most frequent cause of cancer death worldwide, and is one of the 
most aggressive cancers, with mortality rates nearly equal to incidence rates.21 Non‐O 
individuals have a 25% greater risk of stomach and pancreatic cancer, with a 17% overall greater 
risk of pancreatic cancer alone; when compared to blood group O, the risk of exocrine pancreatic 
cancer is highest in blood group B (OR, 1.72), and lower for blood groups AB (OR, 1.51) and A 
(OR, 1.32);11 secretor status had no significant effect on this risk, but the behavior of H. pylori , 
which is also influenced by blood group, may have an influence on risk.1 Non‐O blood group 
individuals infected with CagA negative H. pylori have an even higher risk for pancreatic cancer 
(OR = 2.78).21 The higher rate of pancreatic cancer in non‐O blood group individuals may have 
been explained by a genome‐wide association study, which found that the SNP rs505922 mapped 
to the first intron of the ABO blood group gene in the 9q34 locus and was in complete linkage 
disequilibrium with the O/non‐O allele.45 Other studies have found that blood group O is 
strongly associated with pancreatic disease in patients with Von Hippel‐Lindau (VHL) syndrome 
and is significantly correlated with solid pancreatic lesions in patients with pancreatic 
neuroendocrine tumors (PNETs); VHL patients have a high risk of developing multiple tumors 
throughout the body and their risk of developing both benign and malignant PNETs is 8–17%.46 
 
Multiple Endocrine Neoplasia Type I 
 
In 105 patients diagnosed with multiple endocrine neoplasia type I (MENS‐1), 46 (43.8%) were 
diagnosed with a neuroendocrine tumor; of these 46 patients, 14 had more than one tumor for a 
total of 60 tumors, located in the duodenum (n = 13), stomach (n = 3), lung (n = 5), pancreas (n = 
34), gallbladder (n = 1), or thymus (n = 4).47 In patients with metastatic tumors, 16 of 17 (93.8%) 
had blood group O, while 32 of 43 (74.4%) with benign tumors were blood group O; in patients 
with neuroendocrine tumors, 35 of 46 (76.1%) had blood group O, while only 31 of 59 (52.5%) 
with non‐neuroendocrine tumors were blood group O.47 Of the 59 patients with non‐
neuroendocrine tumors, 31 (52.5%) were blood group O, 15 (25.4%) were blood group A, 7 
(11.9%) were group blood B, and 6 (10.2%) were blood group AB, while of the 46 patients with 
neuroendocrine tumors, 35 (76.1%) were blood group O, 9 (19.6%) were blood group A, 2 
(4.3%) were blood group B, and none were blood group AB.47 Blood group AB is found in 4% 
of the general population, and was found in 3.8% of the study cohort, so the absence of group 
AB in patients with neuroendocrine tumors was notable.47 
 
Cancer of the Colon/Rectum 
 
Increased activity of the α1,2‐fucosyltransferase of the FUT2 gene (Secretor) and the α1,4‐
fucosyltransferase of the FUT3 gene (Lewis) appear to be involved in the development and 
control of cancers of the distal colon; Type 1 and Type 2 chains and Lewis antigens are normally 
present in the fetal colon and disappear in healthy adults, but they reappear in adults who have 
distal colon cancers.1, 49 In the normal colon, only Type 1 chains are expressed by secretors, 
while no Type 1 or Type 2 chains are expressed by nonsecretors in normal or cancerous colon 
tissue.48 In normal colon and colon cancer tissue, secretor status also determines whether the H 
antigen (blood group O) expresses.48 The secretory part of the goblet cells in the normal colon is 
responsible for expression of blood group antigens.49 Blood group A antigen is sometimes 
expressed on malignant tumors of group O or group B individuals; about 10% of colon tumors of 
homozygous type O people express A antigen and have N‐acetyl‐galactosaminyltransferase 
activity.1 
 
Metabolic Diseases 
The role of blood groups in metabolic diseases is more complex; this is most likely because they 
are multifactorial diseases that are not controlled by just one gene or antigen. However, some 
intriguing associations have been found which are presented here. 
 
Hypertension 
 
Hypertension can have many different causes, so it is not surprising that different studies have 
found different associations between blood group antigens and hypertension. One study found 
that the rate of hypertension was highest in blood group B, followed by blood group A, and that 
blood group AB had the lowest rate of hypertension,50 while another study reported a link 
between blood group A and systolic blood pressure in Caucasians but not in Blacks.15 In 
essential hypertension due to abnormal erythrocyte sodium and potassium transport, no 
association was found with the ABO, Rh, Duffy, Kidd, P, or MNS blood groups, or with the 
major histocompatibility HLA antigens.51 In essential hypertension due to abnormal erythrocyte 
sodium‐lithium countertransport, no association was found with the MNS blood group 
polymorphism.53 
 
Essential hypertension is diagnosed when secondary forms of hypertension can be ruled out, but 
it can also be diagnosed due to renal stenosis (renovascular hypertension), atherosclerotic or 
fibromuscular etiology, or primary aldosteronism associated with low plasma renin levels; 
individuals with these conditions were compared to normotensive controls and to individuals 
with secondary hypertension, and no significant differences were found in ABO, Rh, Kidd, Kell, 
Duffy, P, haptoglobin, PGM‐1, or acid phosphatase systems.52 However, there were significant 
differences in the frequencies of the MNS blood group antigens when comparing normotensive 
controls with individuals who had essential or renovascular hypertension; when compared to 
normotensives, essential hypertensives were significantly different among Whites, while a 
similar difference was not seen among Blacks.52 Three distinctly different phenotypic 
frequencies were seen when individuals with atherosclerotic renovascular hypertension were 
compared to essential hypertensives and normotensives.52 
 
Hyperlipidemia 
 
Studies since the early 1980s have investigated the genetic basis for differences in LDL 
cholesterol, HDL cholesterol, and triglycerides, and several have found an association between 
the MN blood group and LDL cholesterol levels.54 Participants in a dietary intervention program 
with homozygous MM and NN genotypes (47%) had similar responses to a low‐fat diet, which 
resulted in almost all of the reported reduction in LDL cholesterol; in contrast, those with the 
heterozygous MN genotype (53%) had little or no response to the low‐fat diet.54 This finding is 
relevant when prescribing a low‐fat diet for LDL cholesterol management because it indicates 
that about half of the general population at large would have a similar response to a low‐fat 
diet.54 
 
Researchers have also investigated the association between ABO blood group antigens and 
hyperlipidemia. One study reported that total cholesterol, LDL cholesterol, and triglycerides 
were higher, and HDL cholesterol was lower, in blood groups A and B, and that blood group AB 
was protective for hyperlipidemia,50 while another study reported that blood group A was 
associated with higher total cholesterol and LDL cholesterol, but reported no association with 
HDL cholesterol.15 
 
Perhaps the most interesting finding was the association of ABO and secretor blood groups with 
serum levels of intestinal alkaline phosphatase (I‐ALP) and apolipoprotein B‐48 (apo B‐48); I‐
ALP is required for transport of chylomicrons from the intestines into the circulation and is 
therefore a marker for chylomicron absorption, and apo B‐48 is a protein that stabilizes the 
chylomicron membrane, and is therefore a marker for chylomicron production.56 There are 
significant differences in serum I‐ALP and apo B‐48 between blood group O and B secretors and 
all other blood groups; the O and B secretors have very elevated serum levels of these markers 
compared with blood group A/AB secretors and nonsecretors of all blood groups.56 
 
ABO nonsecretors only have about 20% of the serum I‐ALP of secretors, and among secretors, 
blood group A has very low activity (2.8 ± 1.1 IU/L; mean ± SEM) compared to blood group B 
and O (14.1 ± 1.1 IU/L and 19.0 ± 2.5 IU/L, respectively).55 It is thought that I‐ALP binds with 
ABO antigens on RBCs of nonsecretors and is also adsorbed by the A antigens of secretors, 
therefore being rapidly eliminated from circulation in these individuals, but the soluble 
circulating antigens of O and B secretors preferentially bind with I‐ALP and prevent its 
elimination in these individuals.56 Blood group A individuals also have lower serum apo B‐48 
levels, which may be due to a genetic down‐regulation of I‐ALP activity in their intestines, 
resulting in reduced chylomicron secretion56 and possibly lower serum cholesterol levels. 
 
Diabetes Mellitus 
 
A large prospective study in France found no association between risk of type 2 diabetes mellitus 
(T2DM) and Rh blood group, but those in blood group O had the lowest risk of T2DM while 
blood group B individuals were at the highest risk, followed by group AB and then group A 
people, but the risk for group AB individuals did not reach statistical significance.19 When ABO 
and Rh groups were evaluated together, blood group B+ individuals had the highest risk, 
followed by group AB+, then A− and then A+ individuals, but no difference in risk was seen for 
the other groups.19 When adjusted for metabolic covariates (fasting blood glucose and lipids), 
blood group AB individuals had the highest risk of T2DM (OR, 1.95), followed by group B (OR, 
1.26) and group A (OR, 1.21) as compared with blood group O individuals, who had the lowest 
risk.19 
 
Other studies have reported contradictory results: a study in Yemen reported that the highest 
random blood sugar and insulin levels were found in blood group A, while blood group AB 
showed a protective effect;50 a study in Iraqi individuals reported higher total cholesterol, higher 
blood glucose, and higher blood pressure in blood group O individuals, followed by lower risk in 
group A, group B, and then group AB individuals, who had the lowest risk;19 a large study in 
Bangladesh reported no association between ABO blood groups and T2DM; and a study in 
Malaysia found lower risk of T2DM in blood groups A and O.57 It has also been reported that 
nonsecretors are more likely to have T2DM.15 
 
Convincing evidence has been reported of a genetic association in those of European ancestry 
between nonsecretor status (se/se ; homozygous for the A/A alleles of the FUT2 gene) and 
insulin‐dependent type 1 diabetes mellitus (T1DM). In the case–control population, the odds 
ratio for nonsecretor status was 1.29 (p = 7.3 × 10−14); in the diabetic family population, the 
relative risk for nonsecretor status was 1.22 (p = 6.8 × 10−6); and the combined results clearly 
indicated a locus for T1DM in the FUT2 gene (p = 4.3 × 10−18).30 
 
The I‐ALP findings by blood group for diabetes were similar to the findings for hyperlipidemia, 
with significantly higher serum I‐ALP and total ALP levels in blood group B and O secretors 
(including controls) when compared to A secretors or ABO nonsecretors, but no significant 
difference in serum I‐ALP or total ALP between A secretors and ABO nonsecretors (including 
controls).60 However, when comparing blood group B and O secretor diabetics to controls, I‐
ALP activity was similar between type 1 and type 2 diabetics but significantly higher in both 
types than in the controls; similarly, there was no significant difference in I‐ALP activity 
between type 1 and type 2 diabetics in the A secretor and ABO nonsecretor groups, but both 
types of diabetics had significantly higher I‐ALP activity than the controls in these groups.60 
 
Additional comparisons were made between the diabetics and controls in the group B and O 
secretors: in most cases, fasting I‐ALP activity was higher in the diabetics than in the controls; 
both types of diabetics had significantly higher liver ALP activity than the controls; type 2 
diabetics had higher liver ALP than type 1 diabetics; and type 2 diabetics also had more 
abnormal ALT and GGT values than type 1 diabetics.60 Disturbed liver function could impair 
clearance of I‐ALP by the liver and would explain the higher ALP levels found in the diabetics; 
high I‐ALP has been reported in patients with cirrhosis of the liver.60 
 
The Role of the Microbiome 
 
Considerable research has focused on the role of intestinal bacteria in the development of 
diabetes. There are significant differences between the composition of the gut microbiome in 
healthy children and children with T1DM, and it is believed that T1DM occurs as a result of a 
pathogenic inflammatory response resulting in damage to the β‐cells of the pancreas.59 In 
addition, intestinal bacterial strains have been identified that can regulate the immune system and 
induce antigen‐specific pathogenic T cells, which may be involved in the development of 
T1DM.59 Differences were also found in both phylum and class levels for those with newly 
diagnosed T2DM, those who were prediabetic, and those with normal glucose tolerance, 
indicating that the progression of glucose intolerance is associated with specific changes in the 
gut microbiome.59 
 
Obesity is strongly correlated with T2DM, but there are metabolically normal obese people who 
are insulin sensitive and euglycemic, and metabolically obese normal weight people who have 
metabolic syndrome despite maintaining a healthy weight.58 In addition, discordance in obesity 
between monozygotic and dizygotic twins clearly indicates that other factors than genetics are 
involved in obesity; fecal transplants between fat and thin mice have resulted in changes in 
metabolism, morphology, and composition of the gut microbiome to match the donor 
mouse.59 There is a strong associate between obesity and alterations of the gut microbiome, but it 
is not known whether these changes are a consequence or a cause of obesity.59 
 
CONCLUSION 
 
There is compelling evidence that risks for disease are related to the chemistry of blood, 
including the blood group classification, the structures of A, B, H, and Lewis determinants, and 
the enzymes which induce these structures. How the blood group and surface antigens play a role 
in disease is only beginning to be investigated with sophisticated modern technologies, including 
recent studies of microbiome and metabolome associations with blood groups. ABO antigens 
provide glycoproteins that are degraded by microbes in the mucosal layer of the intestines. A 
small Finnish study recently demonstrated that the blood group of the host has a statistically 
significant association with the composition of the microbiome. Here, the overall profile of the 
mucosal microbes as well as the relative proportions of the major bacterial groups were reported 
to be different when the B antigen was present, as it would be in blood group B or AB 
individuals.72 This study did not distinguish between secretor and nonsecretor status, but it is 
known that secretor status strongly influences the composition of the human intestinal 
microbiome.73 
 
Because we know that the blood type is defined by oligosaccharide structures, it is reasonable to 
believe that differences in biochemical profiles of individuals may also be related to differences 
in blood type, antigens, and secretor status. Metabolomics studies have revealed differences in 
the biochemical profiles based on ethnicity,74, 75 and blood type is also known to be distributed 
differently among different ethnicities.76 Recent work by Sumner and colleagues at the NIH 
Common Fund Eastern Regional Metabolomics Resource Core have demonstrated differences in 
the metabotypes of individuals based on blood groups.77 While research on the metabotypes of 
blood types and the influence on disease and health has just started, this area of research can 
greatly contribute to the identification of targets for the development of nutritional intervention 
strategies, as well as the identification of druggable targets for drug discovery. 
 
BOX 2. METABOLOMICS IN ANTIGEN RESEARCH 
Metabolomics is a robust analytical tool that identifies and quantifies the small metabolites 
produced in living, biological systems, speeds up identification of metabolic biomarkers that 
reflect the physiological status of cells, and reveals metabolic mechanisms of cellular 
activity.78 In humans, it has been used to distinguish the different metabolic profiles of normal 
and sickle cell erythrocytes,79 and to study the mechanisms and pathogenesis of 
osteoarthritis;80 xenobiotic toxicity; liver, breast, colon, and prostate cancer; inflammatory 
bowel disease; liver disease; and Alzheimer's disease.81 Metabolomics has also proven 
invaluable for understanding the pathogenesis of Barth Syndrome;82 metabolic consequences 
of chronic inflammation;83 and metabolic dysregulation, molecular complexities, and nutrient 
imbalances behind type 2 diabetes mellitus (T2DM).84 There is now compelling evidence that 
human commensal microbiota play a significant role in health and disease; the microbiome 
has the ability to generate biochemical compounds in sufficient quantities to be detected in 
blood metabolites,85 and in turn, the composition of the microbiome can be quite affected by 
dietary changes.72, 84 Of more significance is the finding that blood group antigens and secretor 
status are genetically determined host factors that influence the composition of the human 
intestinal microbiome.72, 73 The associations between blood groups and diseases are well 
documented; the use of metabolomics in blood group antigen research would finally reveal the 
complex mechanisms and processes involved. Metabolomics has great potential to streamline 
diagnosis, treatment, monitoring, and prevention of disease, and will greatly simplify 
collaboration between the fields of clinical research, drug development, personalized 
medicine, and personalized nutrition.78, 86 
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